Philadelphia, April 14, 2024 – Researchers from the Epilepsy Neurogenetics Initiative (ENGIN) at Children’s Hospital of Philadelphia (CHOP) have completed a comprehensive natural history study of ...
Researchers from the Epilepsy Neurogenetics Initiative (ENGIN) at Children's Hospital of Philadelphia (CHOP) have completed a comprehensive natural history study of SCN8A-related disorders, which ...
Praxis Precision Medicines has received Breakthrough Therapy Designation (BTD) from the FDA for relutrigine, a sodium channel modulator intended for pediatric treatment of SCN2A and SCN8A ...
Praxis plans to perform an interim analysis of the EMBOLD cohort 2 pivotal trial in Q4 2025, which if positive should serve as the basis of an NDA in early 2026 BOSTON, Nov. 04, 2025 (GLOBE NEWSWIRE) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results